{ "ok": true, "cik": "1613103", "ticker": "MDT", "name": "Medtronic plc", "filings": [ { "form": "8-K", "filed": "2026-09-17", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1613103/000162828026062505/0001628280-26-062505-index.htm" }, { "form": "10-Q", "filed": "2026-09-03", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/0001628280-26-060473-index.htm" }, { "form": "8-K", "filed": "2026-09-01", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1613103/000162828026059697/0001628280-26-059697-index.htm" }, { "form": "DEF 14A", "filed": "2026-08-17", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1613103/000161310326000010/0001613103-26-000010-index.htm" }, { "form": "10-K", "filed": "2026-06-18", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/0001628280-26-044354-index.htm" }, { "form": "8-K", "filed": "2026-06-03", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1613103/000162828026040034/0001628280-26-040034-index.htm" } ], "events12m": 11, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001613103.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1613103" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up Medtronic plc ($MDT). Last filing: 8-K (8.01 Other Events), 2026-09-17. 11 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2026-04-24", "revenue": 36364000000, "revenueGrowth1y": 0.08429495780779428, "revenueGrowthPerYear": 0.0351478888265484, "yearsOfData": 5, "operatingMargin": 0.17784072159278408, "operatingMarginPrior": 0.17756507737722516, "netMargin": 0.1330161698383016, "operatingCashFlow": 7330000000, "capitalSpending": 1904000000, "freeCashFlow": 5426000000, "researchAndDevelopment": 2873000000, "researchShareOfRevenue": 0.07900670993290067, "cash": 1949000000, "longTermDebt": 26173000000, "longTermDebtChange": 0.020708213087902605, "revenueHistory": [ { "fiscalYearEnd": "2022-04-29", "revenue": 31686000000 }, { "fiscalYearEnd": "2023-04-28", "revenue": 31227000000 }, { "fiscalYearEnd": "2024-04-26", "revenue": 32364000000 }, { "fiscalYearEnd": "2025-04-25", "revenue": 33537000000 }, { "fiscalYearEnd": "2026-04-24", "revenue": 36364000000 } ], "totalEquity": 49463000000, "totalAssets": 93028000000, "equityRatio": 0.5317001332932021, "returnOnEquity": 0.09779026747265633, "dividendsPaid": 3639000000, "payoutRatio": 0.7523258217903659, "dividendPerShare": 2.84, "dividendYearsRising": 13, "dividendCut": false, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 30701900358.6884, "high": 44056294770.77984, "baseline": 38843497417.36893, "n": 1471, "band": "b10" }, "ifPaceHeld": { "low": 30701900358.6884, "high": 44056294770.77984 } }, "edgarette": "🔖 Exposure: revenue $36.4B (FY2026), total debt $26.2B. Experience: revenue up 8.4% on the year, up 3.5% a year over 4 years; operating margin 17.8%, up from 17.8%. Soundness: equity 53.2% of assets, return on equity 9.8%, payout 75.2% of profit, dividend per share up 13 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $30.7B and $44.1B next year (method v3, set from 1,471 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (13 filers, $50M+ revenue, electromedical & electrotherapeutic apparatus): operating margin 17.8% against a 7.5% median; growth 8.4% against 8.3%.", "peers": { "sic": 3845, "sicDescription": "Electromedical & Electrotherapeutic Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3845", "growth": [ 0.0833, 14 ], "opMargin": [ 0.0746, 13 ], "equityRatio": [ 0.4702, 14 ], "returnOnEquity": [ -0.0609, 14 ] }, "summary": "Medtronic (MDT) grew revenue 8.4% in FY2026 to $36.4 billion, operating margin 17.8% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 53.2% of assets, and dividend per share up 13 years running. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Medtronic plc against its own record and its peers
Operating marginPeer median 7.5%17.8%Revenue, on the yearPeer median 8.3%8.4%Equity of assetsPeer median 47.0%53.2%Return on equityPeer median -6.1%9.8%Payout of profit75.2%Gold tick: the median of 14–14 peers with $50M+ revenue in electromedical & electrotherapeutic apparatus
", "chartHorizon": "
Handed back now, or kept to compound
Of each dollar of profit75.2% paid out24.8% keptHanded back per share$2.84up 13 years runningGrowth its own profit can fund2.4%retained x return on equityRevenue growth it managed8.4%last year, for comparison

Gold is paid out to shareholders; navy is kept in the business. Retained profit times return on equity is the pace a company can fund from itself. Facts from the filings, not a recommendation.

", "backtest": { "tests": 10, "hits": 9, "rate": 0.9, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:21:30.472Z", "hash": "705a38db2eea8bc1", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Medtronic (MDT) grew revenue 8.4% in FY2026 to $36.4 billion, operating margin 17.8% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 53.2% of assets, and dividend per share up 13 years running. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2026-04-24", "revenue": 36364000000, "totalDebt": 26173000000, "cash": 1949000000 }, "experience": { "revenueGrowth1y": 0.08429495780779428, "revenueGrowthPerYear": 0.0351478888265484, "operatingMargin": 0.17784072159278408, "operatingMarginPrior": 0.17756507737722516, "netMargin": 0.1330161698383016, "freeCashFlow": 5426000000 }, "soundness": { "equityRatio": 0.5317001332932021, "returnOnEquity": 0.09779026747265633, "payoutRatio": 0.7523258217903659, "dividendPerShare": 2.84, "dividendYearsRising": 13, "dividendCut": false, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 3845, "sicDescription": "Electromedical & Electrotherapeutic Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3845", "growth": [ 0.0833, 14 ], "opMargin": [ 0.0746, 13 ], "equityRatio": [ 0.4702, 14 ], "returnOnEquity": [ -0.0609, 14 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 30701900358.6884, "high": 44056294770.77984, "baseline": 38843497417.36893, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 1471, "sizeBand": "b10" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 10, "hits": 9, "rate": 0.9, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:21:30.472Z", "hash": "705a38db2eea8bc1", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001613103.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1613103" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }